Proceeds from exercises of stock options and other stock issuances
Alnylam Pharmaceuticals Proceeds from exercises of stock options and other stock issuances decreased by 68.4% to $13.16M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 73.3%, from $49.37M to $13.16M. Over 4 years (FY 2021 to FY 2025), Proceeds from exercises of stock options and other stock issuances shows relatively stable performance with a 0.4% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher inflows suggest robust employee participation in equity programs, which can be a sign of positive internal sentiment or high compensation utilization.
Detailed definition
This metric captures the cash inflows received from employees and executives exercising stock options or participating i...
Peer comparison
Commonly reported by public companies with significant equity-based compensation structures; often compared against total share-based compensation expense.
financing_proceeds_from_issuance_of_shares_under_incenti_d15335Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $81.86M | $72.39M | $45.04M | $27.12M | $22.50M | $153.02M | $56.71M | $42.37M | $49.39M | $24.81M | $30.89M | $25.86M | $132.78M | $108.04M | $36.28M | $49.37M | $81.22M | $77.74M | $41.70M | $13.16M |
| QoQ Change | — | -11.6% | -37.8% | -39.8% | -17.0% | +580.0% | -62.9% | -25.3% | +16.6% | -49.8% | +24.5% | -16.3% | +413.5% | -18.6% | -66.4% | +36.1% | +64.5% | -4.3% | -46.4% | -68.4% |
| YoY Change | — | — | — | — | -72.5% | +111.4% | +25.9% | +56.2% | +119.5% | -83.8% | -45.5% | -39.0% | +168.8% | +335.5% | +17.4% | +90.9% | -38.8% | -28.0% | +14.9% | -73.3% |
Proceeds from exercises of stock options and other stock issuances at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Alnylam Pharmaceuticals (ALNY) reported proceeds from exercises of stock options and other stock issuances of $13.16M in Q1 2026.
- How has Alnylam Pharmaceuticals's proceeds from exercises of stock options and other stock issuances changed year-over-year?
- Alnylam Pharmaceuticals's proceeds from exercises of stock options and other stock issuances decreased by 73.3% year-over-year, from $49.37M to $13.16M.
- What is the long-term trend for Alnylam Pharmaceuticals's proceeds from exercises of stock options and other stock issuances?
- Over 4 years (2021 to 2025), Alnylam Pharmaceuticals's proceeds from exercises of stock options and other stock issuances has grown at a 0.4% compound annual growth rate (CAGR), from $246.27M to $250.03M.
- What does proceeds from exercises of stock options and other stock issuances mean?
- Cash received from employees buying company stock through incentive plans.